X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-elvitegravir-cobicistat-emtricitabine-tenofovir-alafenamide-tablets-59973.pdf
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-symtuza-210455-darunavir-cobicistat-emtricitabine-tenofovir-alefenamide-80mg-150mg-200mg-10mg-tablets-1633682776.pdf
https://www.fiercepharma.com/marketing/j-j-sponsored-film-about-first-aids-ward-san-francisco-picked-up-for-broader-distribution
https://www.prnewswire.com/news-releases/janssen-presents-new-data-from-first-phase-3-trial-of-a-single-tablet-regimen-in-a-rapid-initiation-model-of-care-demonstrating-safety-and-efficacy-with-symtuza-through-48-weeks-300830670.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211124
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-stribild-203100-elvitegravir-cobicistat-emtricitabine-tenofovir-disoproxil-fumarate-tablets-1544702903.pdf
http://www.pharmatimes.com/news/nhs_england_agrees_to_fund_janssens_symtuza_1254081
http://www.gilead.com/news/press-releases/2018/8/china-national-drug-administration-approves-gileads-genvoya-elvitegravir-cobicistat-emtricitabine-and-tenofovir-alafenamide-a-single-tablet-regimen-for-the-treatment-of-hiv1-infection
https://endpts.com/jj-joins-blockbuster-hiv-combo-race-with-newly-approved-4-in-1-pill/
https://www.biospace.com/article/is-gilead-poised-for-a-comeback-/
https://www.pharmacompass.com/pdf/news/truvada-emtricitabine-tenofovir-disoproxil-fumarateelvitegravir-gs-9350-cobicistat-viiv-healthcare-v-gilead-sciences-1518416906.pdf
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-challenge-of-evotaz-atazanavir-sulfate-and-cobicistat-tablets-1516338002.pdf
https://www.pharmacompass.com/pdf/news/evotaz-atazanavir-and-cobicistat-gilead-sciences-v-mylan-pharmaceuticals-1513579409.pdf
http://www.businesswire.com/news/home/20171025005612/en/Janssen%E2%80%99s-New-Darunavir-Based-Single-Tablet-Regimen-SYMTUZA%C2%AE/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
https://www.pharmacompass.com/pdf/news/janssen-cilag-international-generic-symtuza-receives-approval-in-europe-1506487967.pdf
http://www.prnewswire.com/news-releases/fda-accepts-supplemental-new-drug-application-for-eisais-lenvatinib-for-the-treatment-of-liver-cancer-300526147.html
http://www.pharmatimes.com/news/ec_approves_janssens_symtuza_1206421
http://seekingalpha.com/article/4033080-glaxo-gilead-hiv-battle-epic
https://www.pharmacompass.com/pdf/news/gilead-sciences-cobicistat-elvitegravir-emtricitabine-tenofovir-alafenamide-fumarate-approved-in-us-1474376630.pdf
http://www.fiercepharma.com/marketing/gilead-increases-lead-against-viiv-hiv-fda-approval-for-descovy
http://www.fiercebiotech.com/story/gilead-gains-next-gen-hiv-approval-fda-it-looks-beat-back-competition/2016-04-05
http://www.pharmatimes.com/Article/16-04-01/NHS_England_funds_Janssen_s_HIV_pill_Rezolsta.aspx
http://www.fiercebiotech.com/story/gileads-latest-hiv-cocktail-wins-fda-approval-blockbuster-pedigree/2016-03-01
http://twofourinsight.com/analyzing-data-earliest-market-entry-subsequent-anda-filers/
http://www.biospace.com/News/three-biotech-stocks-you-dont-have-to-constantly/407378/source=TopBreaking
http://www.pharmatimes.com/Article/15-11-24/EU_clears_single_pill_HIV_therapy_Genvoya.aspx
http://www.fiercebiotech.com/story/gilead-sanofi-singled-out-worst-offenders-failing-disclose-trial-data/2015-11-12
http://www.fool.com/investing/general/2015/11/03/viiv-healthcare-attacking-but-gilead-prepares-to-s.aspx
http://www.fiercepharmamarketing.com/story/janssens-latest-prezcobix-effort-taps-hiv-activists-curate-patient-story-co/2015-09-21
http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2015/06/nce-exclusivity-challenges-are-hot-hot-hot-ferring-lets-loose-with-the-latest-lawsuit-challenging-de.html
http://www.bizjournals.com/sanfrancisco/blog/biotech/2015/04/gilead-gild-hiv-aids-taf-tenofovir.html
http://www.gilead.com/news/press-releases/2015/2/gilead-announces-phase-3-results-for-investigational-oncedaily-single-tablet-hiv-regimen-containing-tenofovir-alafenamide-taf
http://www.janssentherapeutics.com/sites/default/files/pdf/PressRelease01292015.pdf
http://www.janssentherapeutics.com/sites/default/files/pdf/PressRelease01292015.pdf
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002819/human_med_001817.jsp&mid=WC0b01ac058001d124
Market Place
Share 
